-
20/20 BioLabs meets with East Asia partners to explore expansion
-
20/20 BioLabs reaches standstill deal on Series E preferred stock
-
20/20 BioLabs reports Q2 revenue growth, outlines Medicare strategy
-
20/20 Biolabs prepares contingency plans for Ebola and Hantavirus testing
-
Maxim Group Starts 20/20 Biolabs (AIDX) at Buy
-
BIO-key International, 20/20 Biolabs, Society Pass, and Soligenix Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
-
20/20 BioLabs begins trading on NASDAQ under ticker AIDX

